Raymond James added Ionis Pharmaceuticals (IONS) to the firm’s Analyst Current Favorites list saying the recent pullback in the shares is unwarranted. The firm has a Strong Buy rating on the shares with a $61 price target The analyst sees “a lot of untapped value” in Ionis’ pipeline, and believes the setup for the stock over the next 12-18 months is favorable. Raymond James expects approval for Olezarsen in familial chylomicronemia syndrome later in December, “which will help transition the company to commercial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target lowered to $62 from $65 at Piper Sandler
- Ionis Pharmaceuticals price target lowered to $77 from $82 at Wells Fargo
- Ionis Pharmaceuticals Reports Q3 2024 Financial Results
- Morning Movers: CVS Health surges and ODP sinks following Q3 results
- Ionis Pharmaceuticals announces pivotal Phase 3 trial design for ION582